Beta2-microglobulin (beta2-MG) is a pharmacodynamic marker of interferon-beta activity in multiple sclerosis (MS). Its role in the natural course of the disease is not fully known. We analyzed the spontaneous fluctuation of beta2-MG in free-treatment MS patients during a short-time course to quantify beta2-MG as a marker of disease activity/progression. Thirty MS patients were clinically assessed and imaged monthly over a 3-month period. Sera were collected concomitantly for the evaluation of beta2-MG, by means of an enzyme-linked immunosorbent assay. Sera from 20 healthy individuals (HI) were drawn and used as controls. The Mann-Whitney test was used when appropriate and time effect on radiological and biological measures was assessed by means of the random effect models. Eight (26.7%) patients experienced a clinical relapse but three (10%) required steroid treatment. A reduction in the contrast-enhancing lesion load (P = 0.02) and a trend (P = 0.07) toward a decrease in brain parenchyma fraction were observed. Baseline levels of beta2-MG were similar in patients and HI. Patients' beta2-MG values increased over the 3-month time period (P = 0.05) but did not exceed those detected in HI at any time point. These results failed to demonstrate the validity of beta2-MG as a surrogate marker of disease in MS.

BETA2-MICROGLOBULIN SERUM LEVEL IS NOT A MARKER OF DISEASE ACTIVITY IN MULTIPLE SCLEROSIS / Bagnato, F; Zivadinov, R; Cecchinelli, D; Tancredi, Andrea; Grop, A; Pierallini, Alberto; DE LENA, Carlo; Prencipe, Massimiliano; Reale, G; Zorzon, M; Millefiorini, Enrico. - In: EUROPEAN JOURNAL OF NEUROLOGY. - ISSN 1351-5101. - 11:(2004), pp. 455-460. [10.1111/j.1468-1331.2004.00808.x]

BETA2-MICROGLOBULIN SERUM LEVEL IS NOT A MARKER OF DISEASE ACTIVITY IN MULTIPLE SCLEROSIS

TANCREDI, ANDREA;PIERALLINI, Alberto;DE LENA, Carlo;PRENCIPE, Massimiliano;MILLEFIORINI, Enrico
2004

Abstract

Beta2-microglobulin (beta2-MG) is a pharmacodynamic marker of interferon-beta activity in multiple sclerosis (MS). Its role in the natural course of the disease is not fully known. We analyzed the spontaneous fluctuation of beta2-MG in free-treatment MS patients during a short-time course to quantify beta2-MG as a marker of disease activity/progression. Thirty MS patients were clinically assessed and imaged monthly over a 3-month period. Sera were collected concomitantly for the evaluation of beta2-MG, by means of an enzyme-linked immunosorbent assay. Sera from 20 healthy individuals (HI) were drawn and used as controls. The Mann-Whitney test was used when appropriate and time effect on radiological and biological measures was assessed by means of the random effect models. Eight (26.7%) patients experienced a clinical relapse but three (10%) required steroid treatment. A reduction in the contrast-enhancing lesion load (P = 0.02) and a trend (P = 0.07) toward a decrease in brain parenchyma fraction were observed. Baseline levels of beta2-MG were similar in patients and HI. Patients' beta2-MG values increased over the 3-month time period (P = 0.05) but did not exceed those detected in HI at any time point. These results failed to demonstrate the validity of beta2-MG as a surrogate marker of disease in MS.
01 Pubblicazione su rivista::01a Articolo in rivista
BETA2-MICROGLOBULIN SERUM LEVEL IS NOT A MARKER OF DISEASE ACTIVITY IN MULTIPLE SCLEROSIS / Bagnato, F; Zivadinov, R; Cecchinelli, D; Tancredi, Andrea; Grop, A; Pierallini, Alberto; DE LENA, Carlo; Prencipe, Massimiliano; Reale, G; Zorzon, M; Millefiorini, Enrico. - In: EUROPEAN JOURNAL OF NEUROLOGY. - ISSN 1351-5101. - 11:(2004), pp. 455-460. [10.1111/j.1468-1331.2004.00808.x]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/231334
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact